Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Fig. 2

Summary of plasma EBV-DNA levels over time. Median plasma EBV-DNA loads (kIU/L) over time are shown for responders and nonresponders in the pharmacodynamic analysis population. Responses were based on central review. Nonevaluable patients were considered nonresponders. C, Cycle; D, Day; EBV, Epstein–Barr virus; EOT, end of treatment

Back to article page
\